These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36910613)

  • 1. Editorial: Critical complications in pediatric oncology and hematopoietic cell transplant - how far we have come and how much further we must go.
    Agulnik A; Mahadeo KM; Steiner ME; McArthur JA
    Front Oncol; 2023; 13():1148321. PubMed ID: 36910613
    [No Abstract]   [Full Text] [Related]  

  • 2. Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey.
    Ghafoor S; Fan K; Di Nardo M; Talleur AC; Saini A; Potera RM; Lehmann L; Annich G; Wang F; McArthur J; Sandhu H
    Front Oncol; 2021; 11():798236. PubMed ID: 35004323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of pediatric oncology and hematopoietic cell transplant patients receiving extracorporeal membrane oxygenation.
    Maue DK; Hobson MJ; Friedman ML; Moser EA; Rowan CM
    Perfusion; 2019 Oct; 34(7):598-604. PubMed ID: 31018767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacist's role in chimeric antigen receptor T cell therapy.
    Booth JP; Kusoski CL; Kennerly-Shah JM
    J Oncol Pharm Pract; 2020 Oct; 26(7):1725-1731. PubMed ID: 32819199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.
    Krishnamoorthy S; Ghobadi A; Santos RD; Schilling JD; Malone AF; Murad H; Bartlett NL; Alhamad T
    Am J Transplant; 2021 Feb; 21(2):809-814. PubMed ID: 33089906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal Vital Signs Predict Critical Deterioration in Hospitalized Pediatric Hematology-Oncology and Post-hematopoietic Cell Transplant Patients.
    Agulnik A; Gossett J; Carrillo AK; Kang G; Morrison RR
    Front Oncol; 2020; 10():354. PubMed ID: 32266139
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of a Pediatric Early Warning Score in Hospitalized Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients.
    Agulnik A; Forbes PW; Stenquist N; Rodriguez-Galindo C; Kleinman M
    Pediatr Crit Care Med; 2016 Apr; 17(4):e146-53. PubMed ID: 26914628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic CD34
    Lipsitt A; Beattie L; Harstead E; Li Y; Goorha S; Maron G; Gottschalk S; Triplett B; Naik S
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30166. PubMed ID: 36565276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL.
    DiNofia AM; Maude SL
    Hemasphere; 2019 Aug; 3(4):e279. PubMed ID: 31723849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How close are we to CAR T-cell therapy for AML?
    Gill SI
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers.
    Top KA; Pham-Huy A; Price V; Sung L; Tran D; Vaudry W; Halperin SA; De Serres G
    Hum Vaccin Immunother; 2016 Apr; 12(4):931-6. PubMed ID: 26962702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cells: hot news in cancer therapy.
    Hrabovský Š
    Vnitr Lek; 2020; 66(7):420-424. PubMed ID: 33380120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance.
    Ali K; Al-Quteimat O; Naseem R; Malhi SM; Wajdi M; Jahan N; Ansari SH; Shamsi TS
    J Oncol Pharm Pract; 2021 Jun; 27(4):815-820. PubMed ID: 32633660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
    Summers C; Wu QV; Annesley C; Bleakley M; Dahlberg A; Narayanaswamy P; Huang W; Voutsinas J; Brand A; Leisenring W; Jensen MC; Park JR; Gardner RA
    Transplant Cell Ther; 2022 Jan; 28(1):21-29. PubMed ID: 34644605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
    Chodnicki KD; Prasad S
    Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.